Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17611109 | 0.83 | MAOB (0.41) | L3MBTL1PTK2S1PR2S1PR4S1PR3 | |
| SCHEMBL17611149 | 0.82 | MAOB (0.43) | L3MBTL1PTK2S1PR2S1PR4S1PR3 | |
| SCHEMBL27681545 | 0.81 | TRPA1 (0.52) | OPRD1S1PR3 | |
| SCHEMBL24501229 | 0.75 | ESR1 (0.42) | L3MBTL1MAPK1OPRD1PTK2S1PR3 | |
| SCHEMBL13677282 | 0.73 | MAPT (0.42) | L3MBTL1MAPK1PTK2S1PR3TDP1 | |
| SCHEMBL19464637 | 0.73 | MAPT (0.42) | L3MBTL1MAPK1PTK2S1PR3TDP1 | |
| SCHEMBL13104799 | 0.73 | MAPT (0.42) | L3MBTL1MAPK1PTK2S1PR3TDP1 | |
| SCHEMBL3573462 | 0.73 | LMNA (0.56) | OPRD1 | |
| SCHEMBL17611118 | 0.72 | SMN1; SMN2 (0.46) | L3MBTL1S1PR2S1PR4S1PR3TDP1 | |
| SCHEMBL31186171 | 0.72 | PTK2 (0.39) | L3MBTL1MAPK1PTK2S1PR2S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720865-B1 | 2-PYRIDINYLETHYLCARBOXAMIDE DERIVATIVES AND THEIR USE AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2014-12-31 | — | — | EP | disclosed |
| US-7723363-B2 | 2-pyridinylethylcarboxamide derivatives and their use as fungicides | BAYER CROPSCIENCE SA (FR) | 2010-05-25 | — | — | US | disclosed |
| US-20070167491-A1 | 2-Pyridinylethylcarboxamide derivatives and their use as fungicides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-07-19 | — | — | US | disclosed |
| EP-1720865-A1 | 2-PYRIDINYLETHYLCARBOXAMIDE DERIVATIVES AND THEIR USE AS FUNGICIDES | Bayer CropScience S.A. (FR) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005085238-A1 | 2-PYRIDINYLETHYLCARBOXAMIDE DERIVATIVES AND THEIR USE AS FUNGICIDES | BAYER CROPSCIENCE SA (FR) | 2005-09-15 | — | — | WO | disclosed |
| EP-1574511-A1 | 2-Pyridinylethylcarboxamide derivatives and their use as fungicides | Bayer CropScience S.A. (FR) | 2005-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167491-A1 | 2-Pyridinylethylcarboxamide derivatives and their use as fungicides | CYP1A2, PNPO, PFAS | L3MBTL1 3930/4885MAPK1 3144/4885OPRD1 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.